Semaglutide, a weight-loss drug developed by Novo Nordisk, is currently in short supply due to high demand, leading some people to seek out "generic" or compounded versions of the drug instead, Sophie Putka reports for MedPage Today. But obesity specialists warn against using compounded semaglutide since its quality and safety cannot be guaranteed.
